Dynavax Technologies Corporation (DVAX) Price Target Raised to $25.00

Dynavax Technologies Corporation (NASDAQ:DVAX) had its target price boosted by Cantor Fitzgerald from $24.00 to $25.00 in a research report released on Thursday. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

“Launch in 1Q18. Dynavax anticipates launching the product in 1Q18 and previously noted drug supply of over 250,000 vials of product available by the time of launch, with an additional 750,000 vials worth of raw material. In 2H18, Dynavax expects its Dusseldorf plant to manufacture drug supply. We estimate the current supply will support commercialization for over two years, providing ample runway to produce additional supply.”,” the firm’s analyst commented.

A number of other equities research analysts have also recently weighed in on the stock. Royal Bank Of Canada reiterated a buy rating and set a $26.00 price target on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. Cowen and Company reiterated an outperform rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. William Blair reiterated an outperform rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. ValuEngine upgraded shares of Dynavax Technologies Corporation from a sell rating to a hold rating in a research report on Thursday, September 7th. Finally, Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a sell rating to a hold rating in a research report on Friday, August 4th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $25.17.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $20.25 on Thursday. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. During the same period last year, the business earned ($0.90) earnings per share. The business’s revenue for the quarter was down 68.8% on a year-over-year basis. sell-side analysts expect that Dynavax Technologies Corporation will post -1.72 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Dynavax Technologies Corporation (DVAX) Price Target Raised to $25.00” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/dynavax-technologies-corporation-dvax-price-target-raised-to-25-00.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its stake in shares of Dynavax Technologies Corporation by 25.5% in the second quarter. Swiss National Bank now owns 70,978 shares of the biopharmaceutical company’s stock valued at $685,000 after purchasing an additional 14,400 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Dynavax Technologies Corporation by 24.0% in the second quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock valued at $1,496,000 after purchasing an additional 30,036 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Dynavax Technologies Corporation by 50.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 18,000 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 6,000 shares during the period. KCG Holdings Inc. purchased a new position in shares of Dynavax Technologies Corporation in the first quarter valued at approximately $402,000. Finally, Vanguard Group Inc. boosted its stake in shares of Dynavax Technologies Corporation by 14.4% in the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock valued at $10,864,000 after purchasing an additional 230,373 shares during the period. 59.84% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply